{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:47:52Z","timestamp":1787503672708,"version":"build-2736575974"},"reference-count":33,"publisher":"Bioscientifica","issue":"9","funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-072"],"award-info":[{"award-number":["2022-PUMCH-B-072"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82472027"],"award-info":[{"award-number":["82472027"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The efficacy and tolerability of anlotinib in patients with progressive radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC), especially those with prior VEGFR-targeted therapies, are not fully understood. This study reported the long-term outcomes of anlotinib-treated progressive RAIR-DTC patients and evaluated the prognostic value of 68Ga-NOTA-3PRGD2 and 18F-FDG PET\/CT parameters. In this open-label, single-arm, single-center, prospective trial, 20 progressive RAIR-DTC patients were enrolled to receive anlotinib (orally once daily on days 1\u201314 every 3 weeks). The study endpoints included long-term efficacy and safety. The association between PET\/CT parameters at baseline and 6-week assessments and progression-free survival (PFS) was also investigated. The median PFS was 22.5 (95% CI, 16.8\u201327.9) months, the estimated median overall survival was 38.4 (95% CI, 20.4\u201356.4) months, the overall response rate was 47.4% (95% CI, 24.4\u201371.1), the disease control rate was 89.5% (95% CI, 66.9\u201398.7), and the median time to response was 4.1 (range, 1.3\u20138.4) months. There were no significant differences in clinicopathological, efficacy, and safety markers between patients with prior VEGFR-targeted agents (treated group, n = 10) or those without (na\u00efve group, n = 10) (P &amp;gt; 0.05). Higher baseline integrin-expressing tumor burden on 68Ga-NOTA-3PRGD2 PET\/CT and glucose metabolic progression on 18F-FDG PET\/CT 6 weeks after anlotinib treatment were both associated with shorter PFS. Anlotinib showed promise as an effective treatment option for both initial and salvage therapy in progressive RAIR-DTC patients. Integrin- and glucose metabolic-based PET\/CT parameters showed predictive potential in anlotinib-treated patients and warrant further study.<\/jats:p>","DOI":"10.1530\/erc-25-0027","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T10:56:05Z","timestamp":1755082565000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":3,"title":["Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET\/CT prognostic markers"],"prefix":"10.1530","volume":"32","author":[{"given":"Di","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College 1 , ,","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College 2 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College 1 , ,","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College 2 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College 1 , ,","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College 2 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College 1 , ,","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College 2 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College 1 , ,","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College 2 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College 1 , ,","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College 2 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7624-4413","authenticated-orcid":true,"given":"Jun","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Peking University International Hospital, Peking University 3 , ,","place":["Beijing, China"]},{"name":"Department of Medical Oncology, Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute 4 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6095-4728","authenticated-orcid":true,"given":"Yansong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College 1 , ,","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College 2 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"2026070905472434900_bib1","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905472434900_bib2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026070905472434900_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070905472434900_bib4","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of response with selpercatinib in patients with RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070905472434900_bib5","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/cas.13536","article-title":"Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci"},{"key":"2026070905472434900_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"2026070905472434900_bib7","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2026070905472434900_bib8","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"2026070905472434900_bib9","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2026070905472434900_bib10","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1158\/1078-0432.CCR-22-3406","article-title":"Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phase II trial","volume":"29","author":"Chi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026070905472434900_bib11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eprac.2024.02.005","article-title":"Early structural, biochemical, and metabolic responses to anlotinib in patients with progressive radioactive iodine refractory differentiated thyroid","volume":"30","author":"Sun","year":"2024","journal-title":"Cancer Endocr Pract"},{"key":"2026070905472434900_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106694","article-title":"The challenges and opportunities of \u03b1v\u03b23-based therapeutics in cancer: from bench to clinical trials","volume":"189","author":"Gu","year":"2023","journal-title":"Pharmacol Res"},{"key":"2026070905472434900_bib13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s00259-018-4143-8","article-title":"Pretreatment PET\/CT imaging of angiogenesis based on (18)F-RGD tracer uptake may predict antiangiogenic response","volume":"46","author":"Li","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070905472434900_bib14","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1530\/ERC-18-0007","article-title":"PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer","volume":"25","author":"Wang","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026070905472434900_bib15","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2967\/jnumed.115.160648","article-title":"68Ga-NOTA-PRGD2 PET\/CT for integrin imaging in patients with lung cancer","volume":"56","author":"Zheng","year":"2015","journal-title":"J Nucl Med"},{"key":"2026070905472434900_bib16","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European organization for research and treatment of cancer (EORTC) PET study group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"key":"2026070905472434900_bib17","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3390\/cancers14081868","article-title":"Assessment of treatment response to lenvatinib in thyroid cancer monitored by F-18 FDG PET\/CT using PERCIST 1.0, modified PERCIST and EORTC criteria-which one is most suitable?","volume":"14","author":"Rendl","year":"2022","journal-title":"Cancers"},{"key":"2026070905472434900_bib18","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1210\/clinem\/dgad697","article-title":"Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer","volume":"109","author":"Mu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905472434900_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamaoncol.2021.6268","article-title":"Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: the REALITY randomized clinical trial","volume":"8","author":"Lin","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026070905472434900_bib20","doi-asserted-by":"crossref","first-page":"e3027","DOI":"10.1210\/clinem\/dgab196","article-title":"Long-term results of a phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer","volume":"106","author":"Lin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905472434900_bib21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070905472434900_bib22","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.29395","article-title":"A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment","volume":"121","author":"Cabanillas","year":"2015","journal-title":"Cancer"},{"key":"2026070905472434900_bib23","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1158\/1078-0432.CCR-22-3613","article-title":"Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer","volume":"29","author":"Lin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026070905472434900_bib24","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1089\/thy.2021.0307","article-title":"The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase II clinical trial","volume":"31","author":"Huang","year":"2021","journal-title":"Thyroid"},{"key":"2026070905472434900_bib25","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamaoncol.2015.3113","article-title":"JAMA oncology patient page. Performance status in patients with cancer","volume":"1","author":"West","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026070905472434900_bib26","doi-asserted-by":"crossref","first-page":"42252","DOI":"10.18632\/oncotarget.15036","article-title":"Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"2026070905472434900_bib27","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cen.12057","article-title":"Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET","volume":"78","author":"Marotta","year":"2013","journal-title":"Clin Endocrinol"},{"key":"2026070905472434900_bib28","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1507\/endocrj.EJ17-0104","article-title":"Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma","volume":"64","author":"Masaki","year":"2017","journal-title":"Endocr J"},{"key":"2026070905472434900_bib29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1089\/thy.2020.0235","article-title":"Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter phase II trial","volume":"31","author":"Lin","year":"2021","journal-title":"Thyroid"},{"key":"2026070905472434900_bib30","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1210\/jc.2015-3989","article-title":"Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer","volume":"101","author":"Robinson","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905472434900_bib31","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1210\/clinem\/dgab278","article-title":"[18F]-FDG-PET\/CT correlates with the response of radiorefractory thyroid cancer to lenvatinib and patient survival","volume":"106","author":"Valerio","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905472434900_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/cancers13020317","article-title":"(18)F-FDG-PET\/CT in patients with advanced, radioiodine refractory thyroid cancer treated with lenvatinib","volume":"13","author":"Ahmaddy","year":"2021","journal-title":"Cancers"},{"key":"2026070905472434900_bib33","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-19-1098","article-title":"Targeted radionuclide therapy in patient-derived xenografts using (177)Lu-EB-RGD","volume":"19","author":"Zhao","year":"2020","journal-title":"Mol Cancer Ther"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/9\/ERC-25-0027.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/9\/ERC-25-0027.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0027\/145502\/erc-25-0027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0027\/145502\/erc-25-0027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:47:33Z","timestamp":1783590453000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/9\/e250027\/26014\/Anlotinib-in-progressive-RAI-refractory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0027","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"e250027"}}